ABB
31.3.2022 06:48:02 CEST | Business Wire | Press release
ABB will launch on April 1, 2022 its previously announced new share buyback program of up to $3 billion. Based on the current ABB share price this represents a maximum of approximately 89 million shares. The maximum number of shares that may be repurchased under this new program on any given trading day is 1,262,310.
This new program is consistent with ABB’s capital allocation principles and its capital structure optimization program targeting to maintain a strong investment grade rating. As part of this program, the company intends to return to its shareholders the remaining $1.2 billion of the $7.8 billion of cash proceeds from the Power Grids divestment. Since July 2020, ABB repurchased a total of 218,686,689 shares for a total amount of approximately $6.6 billion.
The total number of ABB’s issued shares is 2,053,148,264 including the 88,403,189 shares approved for cancellation at ABB’s 2022 Annual General Meeting (AGM). ABB currently owns approximately 124 million treasury shares.
The share buyback program is for capital reduction purposes and will be executed on a second trading line on the SIX Swiss Exchange (Valor: 35.767.961; ISIN: CH035 767 961 9). It is planned to run from April 1, 2022 until March 22, 2023. At the company’s AGM on March 23, 2023, ABB intends to request shareholder approval to cancel the shares purchased through this new program as well as those shares purchased under the previous program that were not proposed for cancellation at ABB’s 2022 AGM.
The share buyback program will be managed by a bank mandated by ABB that, based on the trading instructions given by ABB to the bank, will make its trading decisions concerning the timing of share repurchases independently of ABB. ABB can change these parameters outside of its closed periods and if it is not in possession of any inside information.
The purchase price per share will not exceed the higher of the price of the last independent trade on the ordinary trading line on the SIX Swiss Exchange and the highest current independent bid price on the ordinary trading line on the SIX Swiss Exchange. In addition, customary spreads on purchases on the second trading line on the SIX Swiss Exchange will be paid, observing the limitations of the Ordinance on Financial Market Infrastructures and Market Conduct in Securities and Derivatives Trading (FMIO). Payment for the shares will be made in cash.
The buyback program is being carried out in accordance with the Ordinance on Financial Market Infrastructures and Market Conduct in Securities and Derivatives Trading (FMIO), the Market Abuse Regulation (EU) No 596/2014 and the Commission Delegated Regulation (EU) No 2016/1052. Weekly updates on the program will be published on ABB’s investor relations website at https://global.abb/group/en/investors/investor-and-shareholder-resources/share-buybacks and issued by press release.
ABB (ABBN: SIX Swiss Ex) is a leading global technology company that energizes the transformation of society and industry to achieve a more productive, sustainable future. By connecting software to its electrification, robotics, automation and motion portfolio, ABB pushes the boundaries of technology to drive performance to new levels. With a history of excellence stretching back more than 130 years, ABB’s success is driven by about 105,000 talented employees in over 100 countries. www.abb.com
Important notice about forward-looking information
This press release includes forward-looking information and statements concerning the share buyback program. These statements are based on current expectations, estimates and projections about the factors that may affect our future performance, and are generally identifiable by statements containing words such as “intends”, “expects,” “plans”, or similar expressions. However, there are many risks and uncertainties, many of which are beyond our control, that could affect our ability to achieve any or all of our stated targets. Factors that could cause such differences include, among others, business risks associated with the volatile global economic environment and political conditions, changes in governmental regulations and currency exchange rates and such other factors as may be discussed from time to time in ABB Ltd’s filings with the U.S. Securities and Exchange Commission, including its Annual Reports on Form 20-F. Although ABB Ltd believes that its expectations reflected in any such forward-looking statement are based upon reasonable assumptions, it can give no assurance that those expectations will be achieved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220330005873/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 20266.5.2026 12:30:00 CEST | Press release
Compass management will host a conference call at 8:00 am ET (1:00 pm UK) Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter ended March 31, 2026, and provide an update on recent developments, on May 13, 2026. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on May 13, 2026. A live webcast of the call will be available on the Compass Pathways website at: https://events.q4inc.com/attendee/144892287. The webcast will be archived for 30 days. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new p
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)6.5.2026 12:25:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to thirteen newly hired non-executive employees. The equity awards were granted on May 1, 2026 and consisted of options to purchase an aggregate of 125,335 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 59,625 shares. The options have an exercise price per share equal to $9.01, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Aircall Acquires Vogent to Advance Its AI Voice Agent Built Natively into Business Phones6.5.2026 12:03:00 CEST | Press release
Aircall, the AI-powered customer communications platform trusted by more than 22,000 businesses worldwide, today announced the acquisition of Vogent, an AI voice agent company. The acquisition adds a new layer of specialized voice AI technology to Aircall’s platform – strengthening the technology behind Aircall’s AI Voice Agent and moving it from already great to best-in-class. While AI agents' chat or email based communication channels have exploded in popularity, voice is its own discipline – with unique demands around timing, interruption handling, call flows, and production reliability. Voice channel also comes with the highest expectations from customers, further putting scrutiny around the readiness of the technology. For many businesses deploying AI voice agents, the experience has not lived up to the hype. With Vogent, Aircall enhances its AI Voice Agents with a deeper set of specialized AI technologies, including advanced speech models, more reliable turn-taking, and higher pr
AB InBev Wins Cannes Lions Creative Marketer of the Year for an Unprecedented Third Time6.5.2026 12:03:00 CEST | Press release
The world’s leading brewer’s approach to creativity as a competitive advantage results in strong performance and increased revenues The Cannes Lions International Festival of Creativity has announced AB InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD) as the 2026 Creative Marketer of the Year. The honorary accolade is presented to a marketer that has amassed a body of iconic, Lion-winning work over a sustained period of time. AB InBev’s continued commitment to using creativity as a growth lever across its portfolio resulted in it winning an impressive 37 Lions at last year’s Festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260506536538/en/ AB InBev is the first company in Cannes Lions’ history to be honoured with the award for a third time. Since 2021 the global brewer has embarked on a journey of inorganic to organic growth, betting on creativity as a key competitive advantage that has contributed to strong perfor
BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates6.5.2026 12:00:00 CEST | Press release
Total global revenues of $1.5 billion for the first quarter, an increase of 35% from the prior year Foundational BRUKINSA (zanubrutinib) global revenues of $1.1 billion for the first quarter, an increase of 38% from the prior year Diluted GAAP Earnings per American Depository Share (ADS) of $1.96 for the first quarter; non-GAAP diluted Earnings per ADS of $3.24 for the first quarter BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the first quarter of 2026. John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said: “These strong first-quarter results reinforce BeOne’s continued growth as a global oncology leader, driven by disciplined commercial execution, and underpinned by our established hematology leadership, and an impressive, rapidly emerging solid tumor pipeline. The sustained competitive advantages of our global superhighway for clinical development and manufacturing are now cle
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
